Characterizing soluble immune checkpoint molecules and TGF-β 1,2,3 in pleural effusion of malignant pleural mesothelioma.

Autor: Okita R; Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan. riki0716okita@yahoo.co.jp., Senoo T; Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan., Mimura-Kimura Y; Department of Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan., Mimura Y; Department of Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan., Murakami T; Department of Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.; Department of Pathology, KYURIN/KYURIN PACELL Corporation, 26-67 Morishita-Cho, Yahatanishi-Ku, Kitakyushu, Fukuoka, 806-0046, Japan., Ikeda E; Department of Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.; Department of Pathology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan., Okada M; Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan., Inokawa H; Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan., Aoe K; Department of Medical Oncology, National Hospital Organization Yamaguchi Ube Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Jul 10; Vol. 14 (1), pp. 15947. Date of Electronic Publication: 2024 Jul 10.
DOI: 10.1038/s41598-024-66189-5
Abstrakt: The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) using enzyme-linked immunosorbent assays; three TGF-β isoforms were measured via multiplex assay in PE of patients with fibrinous pleuritis (FP) or MPM, to assess relationships between the levels of six molecules, clinicopathological characteristics, and efficacy of immune checkpoint inhibitors. Soluble forms of CTLA-4, PD-L1, PD-1, TGF-β 1 , TGF-β 2 , and TGF-β 3 were variably produced in PE of FP (n = 34) and MPM (n = 79); we found significant relationships between the six molecules and clinicopathological features. Although none of the three soluble immune checkpoint molecules showed diagnostic or prognostic effects in patients with MPM, TGF-β 2 level in PE is a useful differential diagnostic marker between FP and MPM. Both TGF-β 1 and TGF-β 3 levels are promising prognostic markers for MPM. Moreover, we found that higher baseline levels of PD-1 soluble forms predicted the response to anti-PD1 monotherapy. Our findings identify novel diagnostic, prognostic, and predictive biomarkers for anti-PD1 therapy in patients with MPM.
(© 2024. The Author(s).)
Databáze: MEDLINE